Follow-up Study of Short-Course Chemotherapy for Pulmonary Tuberculosis |
Byoung Whui Choi, Yong Hoon Kim, Jun Hee Woo, Young Hyun Lee, Young Soo Shim, Keun Youl Kim, Yong Chol Han |
Department of Internal Medicine, College of Medicine, Seoul National Uniνersity, Seoul, Korea |
항결핵 단기요법의 추구검사 |
최병휘, 김용훈, 우준희, 이영현, 심영수, 김건열, 한용철 |
|
|
Abstract |
A clinical study was done on 381 pulmonary tuberculosis patients treated with streptomycin,
isoniazid, rifampicin and pyrazinamide (SHRZ).
Out of 381 patients, 197(51. 7%) have completed the prescribed duration or more of the treatment and 184 patients(48. 3%) have dropped out due to various reasons. Among 197 patients who have completed the chemotherapy, 82 patients have been treated beyond the 9 months treatment due to mainly drug resistance and retreatment. The most common cause of premature interruption was drop-out against advice.
One hundred twelve patients have been followed up for more than 6 months after the termination of chemotherapy, and 86 were followed up for more than twelve months. There
₩ere no relapse at all.
Among 279 patients who have been on treatment for more than one month, 58 patients (20.9%) experienced adverse reactions: 22(7.9%) changed the regimen; others unchanged.
The most frequent adverse reaction was hepatotoxicity.
In conclusion, SHRZ for 9 month was very effective, however, change of regimen might be necessary in case of side effect or drug-resistant case. |
|